Detailed Narrative
Strategic Acquisitions Bolster North India Presence
Metropolis Healthcare successfully acquired three key entities: Core Diagnostics, Scientific Pathology (Agra), and Dr. Ahujas' Pathology and Imaging Center (DAPIC) in Dehradun. These acquisitions are pivotal for expanding the company's footprint in North India, with the region's revenue contribution projected to increase from 8% to 14-15% in FY26. Core Diagnostics, a leader in oncology testing, also provides a platform for genomics expansion, aligning with Metropolis's vision for deep technical expertise and doctor connect.
Strong FY25 Performance Driven by B2C and Operational Focus
For FY25, Metropolis reported a robust 12% year-on-year revenue growth, supported by a 6% increase in patient volumes and strategic pricing/mix improvements. The B2C segment was a key growth driver, expanding 17% YoY and now contributing 55% to total revenue. Adjusted EBITDA for FY25 grew 14% YoY to INR 325 crores, achieving a margin of 24.4%, reflecting the company's focus on profitable growth and a strategic shift away from low-margin institutional contracts.
Q4 FY25 Impacted by One-time Costs and Seasonal Factors
Q4 FY25 revenue reached INR 345 crores, a 10% YoY increase, but reported EBITDA was INR 63 crores, impacted by INR 21 crores in one-time📎 expenses. These costs were primarily associated with M&A transaction fees, diligence, tax cases, and a small inventory write-off. Additionally, lower-than-usual revenue in February and a decline in acute testing volumes due to seasonal weather changes temporarily affected Q4 operating performance, though March saw a healthy recovery.
Shift from Infrastructure Build-out to Efficiency and Optimization
After a period of significant investment, including adding almost 90 labs and 2,000 centers in the last four years, Metropolis is now transitioning its focus to execution and optimization. The company plans to slow down new lab additions to a single-digit number in FY26, while accelerating collection center expansion. This strategic shift is expected to ease margin pressure and drive operational efficiencies, with a target of 100 basis points EBITDA margin expansion for the organic business in FY26.
Integration and Profitability Outlook for Acquisitions
Core Diagnostics, with FY25 revenue of approximately INR 108 crores, was at breakeven in Q4 FY25 and is expected to achieve high single-digit EBITDA in FY26, with full integration under the Metropolis brand anticipated within 12 months. Scientific Pathology (FY25 revenue ~INR 25-26 crores) and DAPIC (FY25 revenue ~INR 10-11 crores) are already operating at company-level margins and are expected to integrate within months. The combined EBITDA contribution from these three acquisitions is projected to be INR 20-25 crores in FY26.
Capital Allocation and Future Growth Projections
Metropolis maintains a strong financial position with a net cash surplus of INR 118 crores as of March 31, 2025. Organic business capex is projected to decrease to INR 50-55 crores in FY26, down from INR 60-70 crores in previous years, reflecting the completion of the rapid lab expansion phase. The company anticipates an overall revenue growth of 25-26% for FY26, driven by approximately 12% organic growth and 13-14% contribution from the acquired entities.